These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 25202073

  • 1. The multi-tyrosine kinase inhibitor TKI258, alone or in combination with RAD001, is effective for treatment of human leukemia with BCR-ABL translocation in vitro.
    Eucker J, Zang C, Zhou Y, Li X, Habbel P, Neumann C, Scholz C, Liu H.
    Anticancer Res; 2014 Sep; 34(9):4909-14. PubMed ID: 25202073
    [Abstract] [Full Text] [Related]

  • 2. TKI258, a multi-tyrosine kinase inhibitor is efficacious against human infant/childhood lymphoblastic leukemia in vitro.
    Eucker J, Zang C, Zhou Y, Li X, Habbel P, Schulz CO, Scholz C, Liu H.
    Anticancer Res; 2014 Sep; 34(9):4899-907. PubMed ID: 25202072
    [Abstract] [Full Text] [Related]

  • 3. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro.
    Liu H, Zang C, Schefe JH, Schwarzlose-Schwarck S, Regierer AC, Elstner E, Schulz CO, Scholz C, Possinger K, Eucker J.
    Anticancer Res; 2011 Sep; 31(9):2713-22. PubMed ID: 21868512
    [Abstract] [Full Text] [Related]

  • 4. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Yun SM, Jung KH, Kim SJ, Fang Z, Son MK, Yan HH, Lee H, Kim J, Shin S, Hong S, Hong SS.
    Cancer Lett; 2014 Jun 28; 348(1-2):50-60. PubMed ID: 24657654
    [Abstract] [Full Text] [Related]

  • 5. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
    Liu H, Scholz C, Zang C, Schefe JH, Habbel P, Regierer AC, Schulz CO, Possinger K, Eucker J.
    Anticancer Res; 2012 May 28; 32(5):1627-37. PubMed ID: 22593441
    [Abstract] [Full Text] [Related]

  • 6. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
    Burchert A, Wang Y, Cai D, von Bubnoff N, Paschka P, Müller-Brüsselbach S, Ottmann OG, Duyster J, Hochhaus A, Neubauer A.
    Leukemia; 2005 Oct 28; 19(10):1774-82. PubMed ID: 16136169
    [Abstract] [Full Text] [Related]

  • 7. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Kurosu T, Ohki M, Wu N, Kagechika H, Miura O.
    Cancer Res; 2009 May 01; 69(9):3927-36. PubMed ID: 19366808
    [Abstract] [Full Text] [Related]

  • 8. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
    Nguyen TK, Rahmani M, Gao N, Kramer L, Corbin AS, Druker BJ, Dent P, Grant S.
    Clin Cancer Res; 2006 Apr 01; 12(7 Pt 1):2239-47. PubMed ID: 16609040
    [Abstract] [Full Text] [Related]

  • 9. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J.
    Clin Cancer Res; 2009 Mar 01; 15(5):1686-97. PubMed ID: 19240172
    [Abstract] [Full Text] [Related]

  • 10. PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases.
    Gontarewicz A, Balabanov S, Keller G, Panse J, Schafhausen P, Bokemeyer C, Fiedler W, Moll J, Brümmendorf TH.
    Leuk Res; 2008 Dec 01; 32(12):1857-65. PubMed ID: 18514829
    [Abstract] [Full Text] [Related]

  • 11. Mammalian target of rapamycin inhibitor rapamycin enhances anti-leukemia effect of imatinib on Ph+ acute lymphoblastic leukemia cells.
    Yang X, He G, Gong Y, Zheng B, Shi F, Shi R, Yang X.
    Eur J Haematol; 2014 Feb 01; 92(2):111-20. PubMed ID: 24112092
    [Abstract] [Full Text] [Related]

  • 12. Rottlerin synergistically enhances imatinib-induced apoptosis of BCR/ABL-expressing cells through its mitochondrial uncoupling effect independent of protein kinase C-delta.
    Kurosu T, Tsuji K, Kida A, Koyama T, Yamamoto M, Miura O.
    Oncogene; 2007 May 10; 26(21):2975-87. PubMed ID: 17130834
    [Abstract] [Full Text] [Related]

  • 13. Cleavage of BCR-ABL transcripts at the T315I point mutation by DNAzyme promotes apoptotic cell death in imatinib-resistant BCR-ABL leukemic cells.
    Kim JE, Yoon S, Choi BR, Kim KP, Cho YH, Jung W, Kim DW, Oh S, Kim DE.
    Leukemia; 2013 Aug 10; 27(8):1650-8. PubMed ID: 23434731
    [Abstract] [Full Text] [Related]

  • 14. Activity of the potent dual Abl/Src tyrosine kinase inhibitor FB2 against Bcr-Abl positive cell lines in vitro and in vivo.
    Yuan X, Zhang Y, Zhang H, Jin J, Li X, Liu H, Feng Z, Chen X.
    Leuk Res; 2011 Feb 10; 35(2):237-42. PubMed ID: 20739063
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of PI3K/mTOR overcomes nilotinib resistance in BCR-ABL1 positive leukemia cells through translational down-regulation of MDM2.
    Ding J, Romani J, Zaborski M, MacLeod RA, Nagel S, Drexler HG, Quentmeier H.
    PLoS One; 2013 Feb 10; 8(12):e83510. PubMed ID: 24349524
    [Abstract] [Full Text] [Related]

  • 16. Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL--Inhibition of P-glycoprotein function by 17-AAG.
    Radujkovic A, Schad M, Topaly J, Veldwijk MR, Laufs S, Schultheis BS, Jauch A, Melo JV, Fruehauf S, Zeller WJ.
    Leukemia; 2005 Jul 10; 19(7):1198-206. PubMed ID: 15902298
    [Abstract] [Full Text] [Related]

  • 17. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.
    Soverini S, De Benedittis C, Papayannidis C, Paolini S, Venturi C, Iacobucci I, Luppi M, Bresciani P, Salvucci M, Russo D, Sica S, Orlandi E, Intermesoli T, Gozzini A, Bonifacio M, Rigolin GM, Pane F, Baccarani M, Cavo M, Martinelli G.
    Cancer; 2014 Apr 01; 120(7):1002-9. PubMed ID: 24382642
    [Abstract] [Full Text] [Related]

  • 18. Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib).
    Fei F, Lim M, Schmidhuber S, Moll J, Groffen J, Heisterkamp N.
    Mol Cancer; 2012 Jun 21; 11():42. PubMed ID: 22721004
    [Abstract] [Full Text] [Related]

  • 19. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, Rao R, Rocha K, Herger B, Lee F, Richon V, Bhalla K.
    Clin Cancer Res; 2006 Oct 01; 12(19):5869-78. PubMed ID: 17020995
    [Abstract] [Full Text] [Related]

  • 20. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin.
    Ly C, Arechiga AF, Melo JV, Walsh CM, Ong ST.
    Cancer Res; 2003 Sep 15; 63(18):5716-22. PubMed ID: 14522890
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.